Liao KL, et al. - Researchers used eligible literature up to October 2017, as searched via electronic databases, to assess the impact of combination therapy involving bevacizumab (BEV) on prognosis in newly diagnosed glioblastoma (GB), as well as its safety. They analyzed data from relevant randomized controlled trials focused on progression-free survival (PFS), overall survival (OS), and adverse events (AEs). Using RevMan software, they pooled all the data with the corresponding 95% confidence intervals (CIs). Quantitative assessment of sensitivity analyses and heterogeneity was also carried out. Analysis of six randomized controlled trials revealed superior PFS rate but no improved OS provided by combination therapy involving BEV in newly diagnosed GB.